Disease Burden of Inflammatory Bowel Disease in China from 1990 to 2019 and Its Predictions

Bule Shao,Wenjing Yang,Qian Cao
DOI: https://doi.org/10.2139/ssrn.4181716
2022-01-01
Abstract:Objective: China is one of the largest newly industrialized countries with the burden of inflammatory bowel disease (IBD) rising rapidly. Understanding the epidemiological trends and patterns of IBD in China is crucial for formulating effective strategies to tackle the disease.Methods: The prevalence, incidence, mortality, years of life lived with disability (YLDs), years of lost (YLLs), disability-adjusted life years (DALYs), and annual percentage changes of the above metrics of IBD in China from 1990 to 2019 were extracted from the Global Burden of Disease Study (GBD) 2019. The numbers and rates of incidence and mortality in the next 25 years were predicted.Results: From 1990 to 2019, the cases of IBD in China raised to 484 thousand [95% uncertainty interval (UI) 411-571] and 427 thousand (95% UI 366-498) among males and females, respectively. The age-standardised incidence rate of IBD increased from1.72 per 100,000 population (95% UI 1.44-2.05) to 3.35 per 100,000 population (95% UI 2.88-3.88) among males and from 1.20 per 100,000 population (95% UI 1.02-1.42) to 2.65 per 100,000 population (95% UI 2.29-3.08) among females. The highest incidence rate occurred in people aged 35-39 years. The total YLDs attributed to IBD significantly increased but the YLLs showed a decreasing trend, resulting in minor alterations of the DALYs. In the next 25 years, the incidence of IBD would continue to increase until a plateau and the number of deaths would also increase despite the decrease in the age-standardised mortality rate. Similar trends were observed for both sexes with a slight male predominance.Conclusion: Although China is still a low-endemic area of IBD, the prevalence and incidence of IBD dramatically increased in the past three decades and would continue to increase in the next 25 years. The substantial burden of IBD calls for collaboration between health policymakers, clinicians, and researchers.Funding: None.Declaration of Interest: The authors declare that they have no conflict of interest.Ethical Approval: The institutional review board of the Sir Run Run Shaw Hospital of Zhejiang University determined that the study did not need approval since the data used were publicly available.
What problem does this paper attempt to address?